Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma.

Collection UNKNOWN
CHALK, ALISTAIR; WALKLEY, CARL; BAKER, EMMA; Gupte, Ankita; WAN, SOO-SAN; Stewart, Elizabeth; Loh, Amos; Shelat, Anang A.; M. Gould, Cathryn; Taylor, Scott; Lackovic, Kurt; J. Mutsaers, Anthony; DESAI, JAYESH; B. Madhamshettiwa, Piyush; C.W. Zannettino, Andrew; Burns, Chris; HUANG, DAVID; A. Dyer, Michael; J. Simpson, Kaylene;
(2015)
  • Publisher: Figshare
  • Related identifiers: doi: 10.4225/49/559e18efe779f
  • Subject: Cell Biology | Genetics | Molecular Biology | Cancer | osteosarcoma | shRNA | St Vincents Instutite | Kinase screen | PI3K | mTOR | genome-wide screen | primary osteosarcoma cell cultures
    • FOR: 60102 Bioinformatics

<p><a href="http://www.ncbi.nlm.nih.gov/pubmed/25862761" target="_blank">Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma.</a></p><div><pre>PURPOSE: Osteosarcoma is the most common cancer of bone occu... View more
Share - Bookmark

  • Download from
    figshare via figshare (Collection, 2015)
  • Cite this research product